• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

骨保护素作为心肌保护与反应性炎症标志物的作用：鸡与蛋的悖论。

The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox.

机构信息

Department of Cardiology, Başkent University İstanbul Hospital, İstanbul, Turkey

Department of Endocrinology and Metabolism, Başkent University İstanbul Hospital, İstanbul, Turkey

出版信息

Balkan Med J. 2018 May 29;35(3):225-232. doi: 10.4274/balkanmedj.2018.0579. Epub 2018 Apr 24.

DOI:10.4274/balkanmedj.2018.0579
PMID:29687784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5981118/
Abstract

Cardiovascular disease is one of the most frequent causes of mortality and morbidity worldwide. Several variables have been identified as risk factors for cardiovascular disease. Recently, the role of receptor activator of nuclear factor kappa B, receptor activator of nuclear factor kappa B ligand, and the osteoprotegerin system has been recognized as more important in the pathogenesis of cardiovascular disease. Besides their roles in the regulation of bone resorption, these molecules have been reported to be associated with the pathophysiology of cardiovascular disease. There are conflicting data regarding the impact of osteoprotegerin, a glycoprotein with a regulatory role in the cardiovascular system. The aim of this review is to discuss the current knowledge and the role of osteoprotegerin in cardiovascular disease.

摘要

心血管疾病是全球范围内导致死亡和发病的最常见原因之一。已经确定了一些变量作为心血管疾病的危险因素。最近，核因子κB 受体激活剂、核因子κB 受体激活剂配体和骨保护素系统在心血管疾病发病机制中的作用被认为更为重要。除了在骨吸收调节中的作用外，这些分子还与心血管疾病的病理生理学有关。关于骨保护素的影响存在矛盾的数据，骨保护素是一种在心血管系统中具有调节作用的糖蛋白。本文的目的是讨论骨保护素在心血管疾病中的最新知识和作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d8/5981118/c38bde0cd985/BMJ-35-225-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d8/5981118/c38bde0cd985/BMJ-35-225-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d8/5981118/c38bde0cd985/BMJ-35-225-g1.jpg

相似文献

1
The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox.骨保护素作为心肌保护与反应性炎症标志物的作用：鸡与蛋的悖论。
Balkan Med J. 2018 May 29;35(3):225-232. doi: 10.4274/balkanmedj.2018.0579. Epub 2018 Apr 24.
2
[Osteoprotegerin: regulator, protector and marker].[骨保护素：调节剂、保护剂与标志物]
Orv Hetil. 2008 Oct 19;149(42):1971-80. doi: 10.1556/OH.2008.28470.
3
Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.核因子κB受体激活剂、核因子κB受体激活剂配体及骨保护素在根尖周囊肿中的表达与分布
J Endod. 2015 Aug;41(8):1281-7. doi: 10.1016/j.joen.2015.03.025. Epub 2015 May 5.
4
Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.RANKL-RANK/骨保护素通路在与HIV感染相关的心血管和骨骼疾病中的作用。
AIDS Rev. 2014 Jul-Sep;16(3):123-33.
5
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.骨保护素/RANK/RANKL 系统：血管疾病的关键之骨。
J Endocrinol Invest. 2009;32(4 Suppl):6-9.
6
Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.骨保护素/核因子-κB 受体激活剂/核因子-κB 受体激活剂配体轴在非酒精性脂肪性肝病中的作用。
World J Gastroenterol. 2018 May 21;24(19):2073-2082. doi: 10.3748/wjg.v24.i19.2073.
7
Key roles of the OPG-RANK-RANKL system in bone oncology.OPG-RANK-RANKL系统在骨肿瘤学中的关键作用。
Expert Rev Anticancer Ther. 2007 Feb;7(2):221-32. doi: 10.1586/14737140.7.2.221.
8
The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease.骨保护素/RANKL/RANK 系统在糖尿病血管疾病中的作用。
Curr Med Chem. 2011;18(31):4813-9. doi: 10.2174/092986711797535281.
9
[The OPG/RANKL/RANK system and bone resorptive disease].[骨保护素/核因子κB受体活化因子配体/核因子κB受体活化因子系统与骨吸收性疾病]
Sheng Wu Gong Cheng Xue Bao. 2003 Nov;19(6):655-60.
10
RANKL signaling in bone physiology and cancer.骨生理学和癌症中的RANKL信号传导
Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be.

引用本文的文献

1
Osteoprotegerin as an Emerging Biomarker of Carotid Artery Stenosis? A Scoping Review with Meta-Analysis.骨保护素作为颈动脉狭窄的一种新兴生物标志物？一项包含荟萃分析的范围综述。
Diagnostics (Basel). 2025 Jan 19;15(2):219. doi: 10.3390/diagnostics15020219.
2
Temporal changes in biomarker levels and their association with the early degeneration stage of transcatheter aortic valves in F-fluorodeoxyglucose and F-sodium fluoride positron emission tomography studies.在氟脱氧葡萄糖和氟氟化钠正电子发射断层扫描研究中，生物标志物水平的时间变化及其与经导管主动脉瓣早期退变阶段的关联。
Postepy Kardiol Interwencyjnej. 2024 Sep;20(3):329-337. doi: 10.5114/aic.2024.142403. Epub 2024 Aug 21.
3
Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease.骨保护素（OPG）：稳定型冠状动脉疾病中不良心血管事件的潜在生物标志物。
Health Sci Rep. 2024 Jul 22;7(7):e2253. doi: 10.1002/hsr2.2253. eCollection 2024 Jul.
4
Osteoprotegerin Is Essential for the Development of Endothelial Dysfunction Induced by Angiotensin II in Mice.骨保护素对于血管紧张素 II 诱导的小鼠血管内皮功能障碍的发展是必需的。
Int J Mol Sci. 2024 Jun 11;25(12):6434. doi: 10.3390/ijms25126434.
5
Relationships between Osteopontin, Osteoprotegerin, and Other Extracellular Matrix Proteins in Calcifying Arteries.钙化动脉中骨桥蛋白、骨保护素及其他细胞外基质蛋白之间的关系
Biomedicines. 2024 Apr 11;12(4):847. doi: 10.3390/biomedicines12040847.
6
Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.血浆骨保护素可预测稳定型冠状动脉疾病患者的不良心血管事件：PEACE试验
Front Cardiovasc Med. 2023 Jun 14;10:1178153. doi: 10.3389/fcvm.2023.1178153. eCollection 2023.
7
Differential Angiogenic Induction Impacts Nasal Polyp Tissue Growth.差异性血管生成诱导影响鼻息肉组织生长。
Indian J Otolaryngol Head Neck Surg. 2023 Apr;75(Suppl 1):893-900. doi: 10.1007/s12070-023-03469-y. Epub 2023 Jan 21.
8
Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.骨保护素和 RANKL-RANK-OPG-TRAIL 信号轴在心力衰竭和其他心血管疾病中的作用。
Heart Fail Rev. 2022 Jul;27(4):1395-1411. doi: 10.1007/s10741-021-10153-2. Epub 2021 Jul 27.
9
Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.血清骨保护素与颈动脉内膜中层厚度与射血分数降低的心力衰竭患者的高动脉僵硬度相关。
Diagnostics (Basel). 2021 Apr 24;11(5):764. doi: 10.3390/diagnostics11050764.
10
Underlying factors relating to acute myocardial infarction for coronary artery ectasia patients.冠状动脉扩张患者急性心肌梗死的相关潜在因素。
Medicine (Baltimore). 2020 Sep 4;99(36):e21983. doi: 10.1097/MD.0000000000021983.

本文引用的文献

1
Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease.主动脉血流传播速度、心外膜脂肪厚度和骨保护素水平用于预测非酒精性脂肪性肝病患者的亚临床动脉粥样硬化。
Anatol J Cardiol. 2016 Dec;16(12):974-979. doi: 10.14744/AnatolJCardiol.2016.6706. Epub 2016 Mar 28.
2
Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes.2型糖尿病患者中骨保护素与外周动脉疾病的关联
Arch Cardiovasc Dis. 2015 Aug-Sep;108(8-9):412-9. doi: 10.1016/j.acvd.2015.01.015. Epub 2015 Jul 13.
3
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.透析前慢性肾脏病中的骨保护素和硬化素：血管钙化的潜在相关因素
Nephrol Dial Transplant. 2015 Aug;30(8):1345-56. doi: 10.1093/ndt/gfv081. Epub 2015 Apr 7.
4
Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients.血清骨保护素与根据高血压患者的心踝血管指数评估的动脉僵硬度相关。
J Atheroscler Thromb. 2015;22(3):304-12. doi: 10.5551/jat.25882. Epub 2014 Oct 15.
5
Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.在3至5期慢性肾脏病患者中，血浆骨保护素水平升高与全因死亡风险及动脉粥样硬化相关。
Braz J Med Biol Res. 2014 Nov;47(11):995-1002. doi: 10.1590/1414-431x20144007. Epub 2014 Aug 22.
6
Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study.用于预测冠心病事件新发糖尿病风险的新工具的开发：动脉粥样硬化多民族研究和海因茨·尼克斯多夫召回研究
Atherosclerosis. 2014 Oct;236(2):411-7. doi: 10.1016/j.atherosclerosis.2014.07.035. Epub 2014 Aug 14.
7
Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.骨保护素在代谢综合征中增加，并促进脂肪组织的促炎变化。
Mol Cell Endocrinol. 2014 Aug 25;394(1-2):13-20. doi: 10.1016/j.mce.2014.06.004. Epub 2014 Jul 3.
8
Elevated serum osteoprotegerin is associated with decreased osteoclastic differentiation in stenotic aortic valves.血清骨保护素升高与狭窄主动脉瓣中破骨细胞分化减少有关。
J Physiol Pharmacol. 2014 Jun;65(3):377-82.
9
Influence of pre-analytical and analytical factors on osteoprotegerin measurements.分析前和分析因素对骨保护素测量的影响。
Clin Biochem. 2014 Sep;47(13-14):1279-85. doi: 10.1016/j.clinbiochem.2014.05.006. Epub 2014 May 17.
10
Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients.高血压患者血清骨保护素水平与颈股动脉脉搏波速度的相关性
J Clin Hypertens (Greenwich). 2014 Apr;16(4):301-8. doi: 10.1111/jch.12288. Epub 2014 Mar 19.